{"id":"W4324136309","doi":"10.1200/jco.2023.41.6_suppl.19","title":"Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Clinical endpoint; Enzalutamide; Placebo; Interim analysis; Internal medicine; Pembrolizumab; Randomization; Abiraterone acetate; Oncology; Prednisone; Randomized controlled trial; Androgen deprivation therapy; Surgery; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046588,0.0002665655,0.002756926,0.0003411428,0.0001427341,0.00004052899,0.0001871201,0.0001571559,0.000118816],"category_scores_gemma":[0.001521573,0.0001452056,0.0006202036,0.0004691885,0.0003762073,0.0002113873,0.00004835825,0.0007408478,0.00001765308],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004201053,"about_ca_system_score_gemma":0.005305507,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008706662,"about_ca_topic_score_gemma":0.0002029137,"domain_scores_codex":[0.9949591,0.0005694353,0.00267324,0.0003538971,0.0009269195,0.0005173687],"domain_scores_gemma":[0.9925087,0.003234238,0.001759902,0.000238526,0.001721201,0.0005374001],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9564133,0.006737113,0.008569205,0.0001379909,0.003166191,0.0009657637,0.0005924656,0.0001376231,0.00001990487,0.00003424853,0.001969626,0.02125656],"study_design_scores_gemma":[0.9377599,0.04397925,0.009901082,0.0001447451,0.002605414,0.00002811766,0.0005167478,0.00036369,0.00003811369,0.0001831141,0.004325646,0.0001541173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879789,0.0005244688,0.00008092022,0.004428196,0.0008920458,0.005728362,0.00007841203,0.0000249424,0.0002637732],"genre_scores_gemma":[0.994386,0.001056214,0.0007970362,0.0002495708,0.0005916863,0.0006210353,0.00007463136,0.00004538324,0.002178489],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03724214,"threshold_uncertainty_score":0.9411742,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.21805030031091,"score_gpt":0.538259259351251,"score_spread":0.320208959040341,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}